EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic response to four artemisinin-based combination therapies in Angola, 2021

Pedro Rafael Dimbu, Sarah Labuda, Carolina Miguel Ferreira, Felismina Caquece, Kialanda André, Garcia Pembele, Dilunvuidi Pode, Maria Florinda João, Venceslau Mambi Pelenda, Benjamin Nieto Andrade, Breanna Horton, Culzean Kennedy und 7 weitere

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.01525-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Pedro Rafael Dimbu und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Malaria Control Program, Ministry of Health, Luanda, Angola. Hauptthemen laut MEDLINE: Antimalarials, Artemisinins, Malaria, Falciparum. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: USAID | President's Malaria Initiative (PMI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Monitoring antimalarial efficacy is important to detect the emergence of parasite drug resistance. Angola conducts in vivo therapeutic efficacy studies (TESs) every 2 years in its fixed sentinel sites in Benguela, Lunda Sul, and Zaire provinces. Children with uncomplicated Plasmodium falciparum malaria were treated with artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ), dihydroartemisinin-piperaquine (DP), or artesunate-pyronaridine (ASPY) and followed for 28 (AL and ASAQ) or 42 days (DP and ASPY) to assess clinical and parasitological response to treatment. Two drugs were sequentially assessed in each site in February–July 2021. The primary indicator was the Kaplan-Meier estimate of the PCR-corrected efficacy at the end of the follow-up period. A total of 622 patients were enrolled in the study and 590 (95%) participants reached a study endpoint. By day 3, ≥98% of participants were slide-negative in all study sites and arms. After PCR correction, day 28 AL efficacy was 88.0% (95% CI: 82%–95%) in Zaire and 94.7% (95% CI: 90%–99%) in Lunda Sul. For ASAQ, day 28 efficacy was 92.0% (95% CI: 87%–98%) in Zaire and 100% in Lunda Sul. Corrected day 42 efficacy was 99.6% (95% CI: 99%–100%) for ASPY and 98.3% (95% CI: 96%–100%) for DP in Benguela. High day 3 clearance rates suggest no clinical evidence of artemisinin resistance. This was the fourth of five rounds of TES in Angola showing a corrected AL efficacy

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsArtemisininsMalaria, FalciparumChildHumansArtesunateArtemether, Lumefantrine Drug CombinationAngolaArtemetherAmodiaquineDrug CombinationsPlasmodium falciparum

Stichwörter der Autor:innen

TESfalciparumresistance

Substanzen

AntimalarialsArtesunateArtemether, Lumefantrine Drug CombinationArtemetherartemisininartenimolArtemisininsAmodiaquineDrug Combinations

Autor:innen und Institutionen

  • National Malaria Control Program, Ministry of Health, Luanda, Angola.
  • United States President's Malaria Initiative, United States Centers for Disease Control and Prevention, Luanda, Angola.
  • PSI Angola, Luanda, Angola.
  • Field Epidemiology Training Program, Ministry of Health, Luanda, Angola.
  • National Institute of Health Research, Ministry of Health, Luanda, Angola.
  • United States Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

ORCID-Profile: Mateusz M Plucinski

Förderung

  • USAID | President's Malaria Initiative (PMI)

Zitieren

APA

Dimbu, P. R., Labuda, S., Ferreira, C. M., Caquece, F., André, K., Pembele, G., Pode, D., João, M. F., Pelenda, V. M., Nieto Andrade, B., Horton, B., Kennedy, C., Svigel, S. S., Zhou, Z., Morais, J. F. M., Rosário, J., Fortes, F., Martins, J. F., & Plucinski, M. M. (2024). Therapeutic response to four artemisinin-based combination therapies in Angola, 2021. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01525-23

Vancouver

Dimbu PR, Labuda S, Ferreira CM, Caquece F, André K, Pembele G, et al. Therapeutic response to four artemisinin-based combination therapies in Angola, 2021. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.01525-23

BibTeX
@article{Dimbu2024,
  author = {Dimbu, Pedro Rafael and Labuda, Sarah and Ferreira, Carolina Miguel and Caquece, Felismina and André, Kialanda and Pembele, Garcia and Pode, Dilunvuidi and João, Maria Florinda and Pelenda, Venceslau Mambi and Nieto Andrade, Benjamin and Horton, Breanna and Kennedy, Culzean and Svigel, Samaly S and Zhou, Zhiyong and Morais, Joana F M and Rosário, Joana do and Fortes, Filomeno and Martins, José Franco and Plucinski, Mateusz M},
  title = {Therapeutic response to four artemisinin-based combination therapies in Angola, 2021},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.01525-23}
}
Kostenlos starten →